The U.S. Food and Drug Administration has approved a new biosimilar drug Amjevita that contains adalimumab-atto as an active pharmaceutical ingredient.Amjevita is a biosimilar to previously approved drug Humira manufactured by AbbVie Inc. of North Chicago, Illinois.
Amjevita/adalimumab-atto basic mechanism is inhibition or suppression tumor necrosis factor alpha (TNFa) which is main culprit for inflammatory response in inflammatory diseases (auto-immune) like rheumatoid arthritis, psoriatric arthritis, ankylosing spondylitis etc.It was observed during clinical trial that administration of adalimumab and methotrexate (MTX) provide synergistic effect and doubles the therapeutic efficacy of methotrexate. Apart from these indications Amjevita/adalimumab-atto can also be used in a patho-physiological condition where suppression of immune system is required. This drug is administered through subcutaneous route (sc).
Multiple inflammatory diseases is a group of disorders that belongs to malfunctioning of immune system. Most common examples of these diseases are rheumatoid arthritis, ulcerative colitis, crohn's disease, hidradenitis suppurativa, juvenile idiopathic arthritis. All kinds of auto-immune disorders are treated and managed by following combination of therapy like DMARD's, Immunosuppressants, Steroidal drugs, etc.
Amjevita/adalimumab-atto Side effects
Amjevita is a biosimilar of Humira so, both have almost same kind of indications and side effects. These side effects can be categorized into moderate to severe.
Moderate Side effects
- Generalized weakness
- feeling of numbness
- Body pain
- Shortness of breath
- vision problems
- skin rashes
- swelling on body
Severe Side effectsSevere kind of side effects associated with this drugs are increase risk of
- Infections like respiratory infection, liver and kidney infection.